ESC-HFA 2024: Late-Breaking Science Video Collection
Published: 14 May 2024
-
Views:
1067
-
Likes:
7
-
Views:
1067
-
Likes:
7
-
Up Next
-
2m 54s
-
4m 46s
-
4m 40sPart 2 | Session 7 FINE-HEART: Design & Baseline Characteristics
-
11m 58sPart 2 | Session 8 HFA 24: The RELIEVE-HF Trial: Differential Effects of V-Wave Device
-
15m 26sPart 1 | Session 1 HFA 24 Late-Breaker Wrap Up with Dr Van Spall & Dr Petrie Harriette Van Spall, Mark Petrie
-
10m 15sPart 1 | Session 2 Late-Breaker Discussion: The TITRATE-HF Study Harriette Van Spall, Jasper J Brugts
-
12m 4sPart 1 | Session 3 Late-Breaker Discussion: Insights from the STEP-HFpEF Harriette Van Spall, Mikhail Kosiborod
-
8m 37sPart 1 | Session 4 Late-Breaker Discussion: Findings from PACT-HF Harriette Van Spall, Tauben Averbuch
-
2m 45sPart 2 | Session 1 Remote Patient Monitoring for Patients With Heart Failure: TELESAT Nicolas Girerd
-
5m 3sPart 2 | Session 2 Cordella PA Sensor System in NYHA Class III HF Patients: PROACTIVE-HF Michael Kiernan
-
7m 19sPart 2 | Session 3 Aspirin Avoidance after Implantation of a Fully Magnetically Levitated LVAD: ARIES HM3 Finn Gustafsson
Overview
Discover the latest heart failure data from impactful trials and studies presented at the Heart Failure Association’s annual congress, Heart Failure 2024.
Dive deep into novel data with in-depth and critical discussions led by Late-breaker host Dr Harriette Van Spall and her expert guests.
For quick and practical summaries of the late-breaking trials, watch our 5-minute Expert Interviews conducted with the investigators.
More from this programme
Part 1
Late-breaker Discussions with Dr Van Spall
Part 2
Expert Interviews
About the episode
HFA 24 - We are joined by Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, US) to discuss the findings from a study of four large-scale placebo controlled-trials investigating the timing of cardio-kidney protection with SGLT2 inhibitors.
4 trials that sampled distinct patient populations were enrolled in the trial - the CANVAS program, the CREDENCE trial, DAPA-HF and DELIVER. Across each randomized trial, investigators assessed the relative timing of effects on multiple cardiovascular and kidney endpoints.
Findings showed that heart failure events were strikingly modifiable, and appeared very early. This finding was sustained not just in patients with existing heart failure, but also in populations of patients with kidney disease and type II diabetes. Kidney disease protection took some time to demonstrate between-arm differences in protection. Mortality endpoints were also similar in terms of clinical benefits. In contrast, effects on MACE and heart failure occurred rapidly.
Interview Questions:
- What is the background of this study?
- What is the study design and patient population?
- What were the findings presented at HFA 24?
- Have you come across any results that were surprising or unexpected?
- What are the take-home messages for practice?
- Where are the knowledge gaps, and what are the next steps?
Recorded onsite at HFA 2024, Lisbon.
Support: This is an independent interview conducted by Radcliffe Cardiology.
Editor: Jordan Rance, Mirjam Boros
Video Specialist: Dan Brent
Interviewer: Jonathan McKenna
Faculty Biographies
![Muthiah Vaduganathan](https://assets.radcliffecardiology.com/s3fs-public/author/2024-07/Headshot%20-%20Vaduganathan%20%28002%29.jpeg?VersionId=BA6fDNLJ9amm8XRkOe0U2cJInN1Yj0Rx)
Muthiah Vaduganathan
Co-Director, Center for Cardiometabolic Implementation Science
Dr Muthiah Vaduganathan is a Cardiologist and Clinical Trialist at Brigham and Women’s Hospital and Harvard Medical School, Boston, US. He is co-director of the Center for Cardiometabolic Implementation Science at Brigham and Women’s Hospital. He serves as an Associate Editor of JACC and as US national ambassador to the ESC Heart Failure Association. His research focuses on drug development, clinical trials, and implementation of cardio-kidney-metabolic therapies, and he has authored or co-authored more than 700 peer-reviewed publications. He participates on study leadership of ongoing advanced-phase trials in cardio-kidney-metabolism and heart failure.
Comments